

Sex differences in clinical and prognostic trajectories in patients with idiopathic REM sleep behavior disorder: Insights from the FARPRESTO cohort

Journal of Parkinson's Disease

1–11

© The Author(s) 2025

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/187718X251385422

journals.sagepub.com/home/pkn



Michelangelo Maestri^{1,*}, Michela Figorilli^{2,3,*}, Federico Meloni³, Elisa Casaglia^{2,3}, Marcello Mario Mascia^{2,3}, Martina Mulas³, Federica Provini^{4,5}, Luca Baldelli^{4,5}, Luisa Sambati⁵, Felice Di Laudo⁴, Pietro Mattioli^{6,7}, Beatrice Orso⁶, Mattia Losa^{6,7}, Dario Arnaldi^{6,7}, Luigi Ferini Strambi^{8,9}, Sara Marelli^{8,9}, Alessandra Castelnovo^{8,9}, Francesca Marta Casoni^{8,9}, Michele Terzaghi^{10,11}, Elena Capriglia¹⁰, Gaetano Malomo¹⁰, Valter Rustioni¹⁰, Giuseppe Plazzi^{5,12}, Francesco Biscarini^{4,5}, Claudio Liguori^{13,14}, Mariana Fernandes¹³, Flavia Cirillo¹³, Domeniko Hoxhaj¹, Enrica Bonanni¹, Giacomo Della Marca^{15,16}, Valerio Brunetti^{15,16}, Raffaele Ferri¹⁷, Giuseppe Lanza^{17,18}, Gaia Pellitteri¹⁹, Gianluca Rossato²⁰, Biancamaria Guarnieri^{21,22}, Elena Antelmi²³, Francesca Ingravallo^{24,#} and Monica Puligheddu^{2,3,#}

Abstract

Introduction: There are conflicting findings regarding the influence of sex on idiopathic REM sleep behavior disorder (iRBD) in terms of prevalence and associated clinical characteristics. This study, conducted as part of the Italian multi-center longitudinal FARPRESTO project, aims to explore sex-related differences in the age of onset, iRBD diagnosis,

¹Sleep Disorder Center, Neurology Unit, Azienda Ospedaliero-Universitaria Pisana and Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

²Sleep Disorder Research Center, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy

³Neurology Unit, Azienda Ospedaliero-Universitaria, Cagliari, Italy

⁴Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy

⁵IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

⁶Dept of Neuroscience, University of Genoa, Genoa, Italy

⁷Clinical Neurophysiology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

⁸Vita-Salute San Raffaele University, Milan, Italy

⁹Neurology, Sleep Disorders Center, IRCC San Raffaele Scientific Institute Milan, Genoa, Italy

¹⁰Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

¹¹Unit of Sleep Medicine and Epilepsy, Mondino Foundation IRCCS, Pavia, Italy

¹²Department of Biomedical, Metabolic and Neuroscience, University of Modena and Reggio Emilia, Modena, Italy

¹³Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

¹⁴Sleep Medicine Center, Neurology Unit, University Hospital of Rome Tor Vergata, Rome, Italy

¹⁵Sleep Medicine Unit - UOC di Neurologia - Dipartimento di Neuroscienze, Organi di Senso e Torace - Fondazione Policlinico Universitario Agostino Gemelli IRCCS - 00168, Rome, Italy

¹⁶Department of Neurosciences, Università Cattolica del Sacro Cuore - 00168, Rome, Italy

¹⁷Clinical Neurophysiology Research Unit, Sleep Research Center, Oasi Research Institute-IRCCS, Troina, Italy

¹⁸Department of Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy

¹⁹Clinical Neurology, ASUFC, Udine and Department of Medicine (DMED), University of Udine, Udine, Italy

²⁰Sleep Center, Neurology Dept, IRCCS Sacro Cuore Don Calabria, Negrar, Verona, Italy

²¹Center of Sleep Medicine, Villa Serena Hospital, Città S. Angelo, Pescara, Italy

²²Villaserena Foundation for the Research, Città S. Angelo, Pescara, Italy

²³DIMI Department of Engineering and Medicine of Innovation, University of Verona, Verona, Italy

²⁴Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy

* M.M. and M. F. contributed equally to this study

F.I. and M.P. contributed equally to this study

Corresponding author:

Michela Figorilli, Sleep Disorder Research Center, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Email: michelafigorilli@gmail.com



and phenoconversion, as well as in cognitive and non-motor features and the occurrence of RBD-related injuries among male and female patients with iRBD.

Methods: The FARPRESTO study included 536 iRBD patients recruited from 13 Italian centers. This analysis assessed the age at iRBD diagnosis, diagnostic delay, motor and non-motor symptoms, global cognitive performance, conversion rates to neurodegenerative disorders, and the prevalence of RBD-related injuries at the time of iRBD diagnosis, stratified by sex.

Results: Female patients were older at iRBD diagnosis compared to males (males: 67.8 years, IQR 62.5–72.6; females: 69.8 years, IQR 65.1–74.8; $p = 0.003$). Compared to male patients, female patients exhibited a higher prevalence of orthostatic hypotension (27.9% vs. 16.2%; $p = 0.019$), depression (43.9% vs. 26.6%; $p = 0.010$), and hallucinations (43.9% vs. 26.6%; $p = 0.010$) at iRBD diagnosis. Additionally, self-directed injuries were significantly more frequent in females compared to males at the first visit (71% vs. 53.2%; $p = 0.034$). No significant differences were observed in the phenoconversion rate between sexes.

Conclusion: Although research on sex-related differences in iRBD remains limited, this study highlights the importance of understanding sex-specific characteristics. As diagnostic and therapeutic approaches evolve, incorporating these differences will be essential for tailoring clinical strategies and improving patient outcomes.

Plain language summary

Do Men and Women Experience REM Sleep Disorder Differently? Important Clues from the FARPRESTO Study

REM sleep behavior disorder (RBD) is a condition where people physically act out their dreams, sometimes violently. This can lead to injuries and may be an early sign of brain diseases like Parkinson's. Researchers have long wondered whether men and women experience RBD differently, but past studies have shown mixed results. This study is part of the FARPRESTO project, a large research effort across 13 centers in Italy. It looked at 536 people diagnosed with idiopathic RBD (iRBD), meaning the disorder occurs without a known cause. The goal was to understand how men and women differ in terms of when symptoms start, how long it takes to get diagnosed, and what other symptoms they experience. The study found that women were diagnosed with iRBD at an older age than men. Women also had more issues like low blood pressure when standing (orthostatic hypotension), depression, and hallucinations. Interestingly, women were more likely to hurt themselves during sleep, such as falling out of bed or hitting themselves. However, both men and women had similar chances of developing a neurodegenerative disease later on. These findings show that men and women may experience iRBD in different ways. Understanding these differences can help doctors diagnose the condition earlier and provide better, more personalized care. As research continues, considering sex-specific symptoms could lead to improved treatment and outcomes for patients with RBD.

Keywords

REM sleep behavior disorder, neurodegeneration, sex differences, the FARPRESTO cohort, phenoconversion

Received: 29 March 2025; accepted: 21 September 2025

Introduction

Rapid eye movement (REM) sleep behavior disorder (RBD) is a REM sleep parasomnia characterized by dream enactment behaviors due to the loss of physiological REM sleep muscle atonia. It typically occurs in individuals over 50 years old and is frequently associated with neurological diseases, primarily synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). RBD can also present in an isolated form as idiopathic RBD (iRBD). However, with sufficient follow-up, the majority of iRBD patients eventually develop a neurodegenerative disorder in a process referred to as "phenoconversion".¹

From early observations, a male predominance in RBD presentation has been reported.² However, findings in the

literature remain inconsistent, likely due to methodological variations, including differences in study samples (clinical sample vs. general population) and diagnostic methods, e.g., confirmation through video-polysomnography (vPSG) versus probable RBD diagnosis.³ According to the diagnostic criteria outlined in the International Classification of Sleep Disorders, Third Edition (ICSD-3)⁴ an RBD diagnosis requires both a history of recurrent sleep-related vocalizations and/or complex motor behaviors and the presence of REM sleep without atonia confirmed by vPSG. In contrast, many population-based studies rely on clinical history alone, classifying individuals as having possible or probable RBD (pRBD) without vPSG confirmation.

Takeuchi et al.⁵ recently investigated 43 female and 141 male patients with vPSG-confirmed iRBD, finding that female patients had an older estimated age of onset compared

to males, while no differences were observed in age at diagnosis. This study also reported no sex-related differences in olfactory function or cognitive performance in the same cohort.⁵ Similarly, Fernández-Arcos⁶ analyzed a larger cohort of 41 female and 162 male iRBD patients and found no sex-related differences in age at diagnosis or phenoconversion. While male predominance in RBD remains incompletely understood, other sex-related differences, including those in cognitive or non-motor symptoms, age at onset and phenoconversion, or the presence of self-inflicted or bed partner injuries, are even less clearly defined. Larger longitudinal studies are needed to elucidate the clinical and prognostic trajectories of iRBD based on sex.⁷

The *Risk Factors Predictive of Phenoconversion in Idiopathic REM Sleep Behavior Disorder Italian Study* (FARPRESTO) is a multicenter, longitudinal, retrospective, and prospective Italian project promoted by the Italian Association of Sleep Medicine (AIMS; www.sonnomed.it) and endorsed by the Italian Association of RBD Patients (www.associazionerbd.it). The project currently involves 14 Italian sleep centers.⁸

The aim of this study was to investigate sex-related differences within the FARPRESTO cohort of patients with vPSG-proven iRBD in terms of: a) age at disease onset, age at first clinical visit, and age at phenoconversion; b) cognitive and non-motor characteristics, and c) the occurrence of dream enactment-related injuries.⁸

Patients and methods

All participants in this study were patients with iRBD enrolled in the FARPRESTO study. The data presented in this article were collected as of February 2023, with 536 iRBD patients consecutively recruited from 13 accredited Sleep Medicine Centers across Italy (Bologna – two centers, Cagliari, Genoa, Milan, Pavia, Pisa, Rome Gemelli, Rome Tor Vergata, Verona, Troina, Udine, and Pescara), all members of the Italian Association of Sleep Medicine. The cohort included both previously diagnosed and newly diagnosed iRBD patients, all meeting the ICSD-2 or ICSD-3 diagnostic criteria and aged ≥ 18 years. Because the FARPRESTO cohort includes patients diagnosed both before and after 2014, iRBD diagnoses were made according to ICSD-2 criteria for earlier cases and ICSD-3 criteria for later cases, with the latter providing more detailed specifications for REM sleep without atonia. Because the ICSD-3-Text Revision (2023) postdated most enrollments, diagnoses were adjudicated under ICSD-2 or ICSD-3 as appropriate. The ICSD-3-TR⁹ does not substantively alter the core case definition of vPSG-confirmed iRBD (recurrent REM sleep-related behaviors with REM sleep without atonia), and our case ascertainment is therefore consistent with ICSD-3-TR. Moreover, as this is a clinical rather than a general population sample, potential selection bias, particularly regarding sex distribution, has

been considered in the interpretation of the results. All participants provided signed informed consent.

For each participant, we recorded sex, marital status, age at iRBD diagnosis, and diagnostic delay. Age at iRBD diagnosis referred to the age at the first clinical visit in which the diagnosis of iRBD was established according to ICSD-2 or ICSD-3 criteria. Diagnostic delay was calculated as the time interval between the self-reported onset of RBD symptoms and the date of iRBD diagnosis. Motor symptoms were assessed using the Unified Parkinson's Disease Rating Scale part III (UPDRS III) or the Movement Disorders Society-UPDRS part III (MDS-UPDRS III). Non-motor symptoms (including hyposmia, constipation, urinary dysfunction, erectile dysfunction, orthostatic hypotension, depressive symptoms, and hallucinations) were evaluated in agreement with the FARPRESTO protocol⁸ through semi-structured interviews and/or validated questionnaires, including the Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction (SCOPA-AUT), the Hospital Anxiety and Depression Scale (HADS), and the Beck Depression Inventory (BDI).⁸ Hyposmia was assessed by self-report unless otherwise documented by an objective smell test in the medical record.⁸

To standardize the evaluation of cognitive impairment, the 'MoCA-to-MMSE' conversion tables by Aiello¹⁰ were applied. Similarly, to harmonize UPDRS III and MDS-UPDRS III scores, the formula developed by Goetz et al. was used.¹¹

This study adhered to the principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the local ethics committees of all participating FARPRESTO centers, and informed consent was obtained from all participants. The FARPRESTO study is registered at clinicaltrials.gov (NCT05262543).

Statistical analysis

Due to the non-parametric distribution of data, the Mann-Whitney U test was used to evaluate differences between males and females at the first medical examination (for the overall sample and phenoconverted subjects) and at the second medical examination (for phenoconverted subjects) in the following variables: age at iRBD diagnosis, age at MMSE or MoCA testing, age at RBD onset, age at conversion, age at post-conversion MMSE or MoCA testing, years of education, RBD-related injuries, UPDRS III or MDS-UPDRS III scores, MMSE scores, and BDI scores. In the FARPRESTO protocol, follow-up visits are scheduled at least every 12 months; for the present analysis, we considered the first visit (diagnosis) and the visit at phenoconversion, or the most recent follow-up in non-converted patients, with a median follow-up duration of 2.57 years across participants, reflecting variability in observation periods. Differences in age at iRBD diagnosis and age at RBD onset were also analyzed between patients with and without a history of phenoconversion.

Table 1a. Demographic and clinical data by sex for the overall study sample (continuous variables).

	First medical examination (N 536)		P value
	Males	Females	
N (%)	431 (80.4)	105 (19.6)	-
Marital Status			< 0.001
Married-Cohabiting (N %)	400 (92.8)	70 (66.7)	
Separated-Divorced (N %)	18 (4.2)	6 (5.7)	
Unmarried (N %)	6 (1.4)	12 (11.4)	
Widowed (N %)	7 (1.6)	17 (16.2)	
Age at the iRBD diagnosis (Median - IQR)	67.81 (62.5–72.6)	69.8 (65.1–74.8)	0.003
Age at MMSE MoCA test (Median - IQR)	68.9 (63.5–73.4)	70.7 (66.1–75.8)	0.008
Age at RBD onset (Median - IQR)	63.8 (57.8–69.2)	66.2 (57.8–71.3)	0.120
Education (years) (Median - IQR)	13.0 (8.0–13.0)	8.0 (8.0–13.0)	0.015
Number of lesions (Median - IQR)	2.0 (1.0–3.0)	2.0 (1.0–3.0)	0.640
UPDRS - MDS-UPDRS motor score (Median - IQR)	2.0 (0.0–5.0)	2.0 (0.0–6.0)	0.414
MMSE score (Median - IQR)	29.0 (27.0–30.0)	29.0 (26.0–30.0)	0.160
Depression score (Median - IQR)	5.5 (3.0–13.0)	11.0 (7.0–18.0)	< 0001

Note: The phenoconverted subgroup (n = 121) is included within the overall cohort in this table. Subgroup-specific values are presented in Tables 1b and 2b. IQR = interquartile range; MMSE = mini-mental state examination; MoCA = Montreal cognitive assessment; RBD = REM sleep behavior disorder; UPDRS = Unified Parkinson's Disease Rating Scale; MDS-UPDRS = Movement Disorder Society UPDRS.

The Pearson's chi-squared test was used to analyze differences in categorical variables between males and females at the first medical examination (for the overall sample and phenoconverted subjects) and at the second medical examination (for phenoconverted subjects). These variables included marital status, presence/absence of lesions, oneiric status (defined as the presence of a recollection of dream content), hyposmia (yes/no), constipation (yes/no), urinary dysfunction (yes/no), orthostatic hypotension (yes/no), depression (yes/no), presence/absence of hallucinations, and injuries (to the patient, the partner, or both). For the purpose of statistical analysis, injuries were stratified into self-directed (affecting only the patient) and other-directed (affecting the bed partner) to examine potential differences in their occurrence and associated factors.

Information on injuries was collected for all participants at the first visit using a standardized semi-structured interview, following the FARPRESTO protocol. Injuries were classified as affecting the patient, the bed partner, or both, and self-directed injuries were defined as those sustained by the patient during dream-enactment behaviors. This classification was applied consistently in all analyses. At the second medical examination, lesion data were collected in the same manner, through self-report during a structured medical interview; no additional vPSG was performed.

For the survival analysis, we included all participants with complete follow-up data (n = 320), comprising

individuals who experienced phenoconversion (n = 121) and those who had not converted by their most recent follow-up (n = 199), who were treated as censored. In accordance with the FARPRESTO protocol, follow-up visits are scheduled at least every 12 months. The time-to-event variable was defined as the interval between the date of iRBD diagnosis (first visit) and either the phenoconversion date (for events) or the date of the second clinical follow-up visit (for censored cases). Participants excluded from the Cox regression (n = 217) were removed due to missing values in key variables (n = 216) or automatic software exclusion before the first observed event in their stratum (n = 1). The sex distribution did not differ significantly between included and excluded participants ($\chi^2 = 0.86$, $p = 0.353$), indicating no evidence of sex-related exclusion bias. This approach allowed us to account for variable follow-up durations across participants, rather than relying on two fixed time points. To reduce the risk of model overfitting, covariates were preselected a priori based on clinical relevance and baseline sex-related differences, and only two predictors (sex and age at iRBD diagnosis) were included, ensuring an event-per-variable ratio greater than 10, consistent with recommended standards for Cox regression.

A two-tailed α error threshold of $p < 0.05$ was used to reject the null hypothesis. Statistical analyses were conducted using SPSS® version 20.0 (IBM Corporation, Armonk, NY, USA).

Table 1b. Demographic and clinical data by sex for the phenoconversion group (continuous variables) at first and second medical examinations (time of phenoconversion diagnosis).

	First medical examination			Second medical examination		
	Males	Females	P value	Males	Females	P value
N (%)	97 (80.2)	24 (19.8)	-	97 (80.2)	24 (19.8)	-
Age at the iRBD diagnosis (Median - IQR)	69.36 (67.0–75.4)	66.1 (62.9–69.4)	0.123	-	-	-
Age at MMSE MoCA test (Median - IQR)	69.1 (67.6–75.4)	68.6 (64.6–72.3)	0.158	73.8 (68.3–77.7)	74.0 (69.5–79.7)	0.855
Age at RBD onset (Median - IQR)	66.3 (58.4–70.3)	61.1 (57.9–66.3)	0.313	-	-	-
Age at conversion date (Median - IQR)	-	-	-	73.0 (68.0–77.1)	74.1 (69.8–78.5)	0.412
Education (years) (Median - IQR)	10.0 (5.0–13.0)	8.0 (8.0–13.0)	0.719	-	-	-
Number of lesions (Median - IQR)	2.0 (1.0–3.0)	3.0 (1.0–3.0)	0.426	1.5 (1.0–2.5)	1.5 (1.0–2.5)	1.000
UPDRS - MDS-UPDRS motor score (Median - IQR)	1.5 (0.0–4.0)	2.0 (0.0–3.0)	0.317	10.0 (4.0–15.0)	6.5 (3.5–10.0)	0.170
MMSE score (Median - IQR)	28.0 (25.0–29.0)	30.0 (26.0–30.00)	0.844	27.0 (25.0–28.0)	27.0 (26.0–28.0)	0.083
Depression score (Median - IQR)	9.5 (3.0–14.0)	18.0 (18.0–29.0)	0.002	8.0 (4.0–14.0)	18.0 (14.0–29.0)	0.059

Results

Demographic and clinical data by sex for the overall study sample and the subgroup of subjects with conversion are presented in Tables 1a, 1b, 2a, and 2b.

A total of 121 out of 536 subjects (22.6%) underwent phenoconversion, including 24 out of 105 females (22.9%) and 97 out of 431 males (22.5%). Among males, the diagnoses were: 55 PD (12.8% of males and 10.3% of the total), 31 DLB (7.2% of males and 5.8% of the total), and 9 MSA (2.1% of males and 1.7% of the total). In the female group, 13 were diagnosed with PD (12.4% of females and 2.4% of the total), 8 with DLB (7.6% of females and 1.5% of the total), and 3 with MSA (2.9% of females and 0.6% of the total), according to current diagnostic criteria.⁸ Additionally, two male subjects had an undefined diagnosis because, although they did not meet specific criteria, an extrapyramidal condition was evident. There was no significant difference in the distribution of phenoconversion phenotypes between female and male patients ($p = 0.894$). Among the 415 subjects who did not undergo phenoconversion at the first follow-up visit, there were 81 females and 334 males.

No significant differences were observed in age at iRBD diagnosis or age at RBD onset between patients with and without a history of conversion. In this study, age at iRBD diagnosis refers to the age at the first clinical visit when the iRBD diagnosis was established, while diagnostic delay represents the interval between the self-reported onset of RBD symptoms and the date of iRBD diagnosis.

We also calculated the prodromal duration, defined as the interval between reported RBD symptom onset and phenoconversion. The median duration was 6.92 years in females and 7.11 years in males, with no significant sex-related difference (Mann–Whitney $U = 475.0$, $p = 0.427$).

Female participants were older at diagnosis (mean $\pm$ SD: 69.23 ± 6.57 years vs. 67.00 ± 7.52 years; $p = 0.019$) and showed higher MMSE scores (28.17 ± 2.04 vs. 27.60 ± 2.39 ; $p = 0.049$) and MoCA scores (25.74 ± 3.38 vs. 24.43 ± 4.21 ; $p = 0.012$) compared with males. Notably, there was no significant difference in the age of RBD onset.

Education level was significantly higher in males at the time of iRBD diagnosis (median 13.0 years, IQR 8.0–13.0) compared to females (median 8.0 years, IQR 8.0–13.0; $p = 0.015$). However, no significant differences in education level were found among female and male patients who underwent phenoconversion. Aside from females being older at iRBD diagnosis, no significant sex differences were observed in age at RBD symptom onset, age at phenoconversion, or age at post-conversion MMSE/MoCA testing. The presence of orthostatic hypotension (29.6% vs. 20.2%; $p = 0.043$), depression (29.6% vs. 17.3%; $p = 0.006$), and hallucinations (11.9% vs. 5.4%; $p = 0.041$) was more frequent in females than in males in the entire group. In the phenoconverted subgroup, hallucinations and depression were more frequently observed in females at the time of the first visit.

Additionally, injuries affecting patients were significantly more frequently reported in females (71.0%) compared to

Table 2a. Clinical data by sex for the overall study sample (categorical variables).

		First medical examination		P value
		Males N (%)	Females N (%)	
lesions	Yes	234 (66.1)	62 (70.5)	0.451
	Not	120 (33.9)	26 (29.5)	
oneiric status	Yes	298 (85.6)	66 (80.5)	0.306
	Not	50 (14.4)	16 (19.5)	
hyposmia	Yes	152 (47.1)	37 (44.0)	0.626
	Not	171 (52.9)	47 (56.0)	
constipation	Yes	139 (41.1)	43 (48.9)	0.226
	Not	199 (58.9)	45 (51.1)	
urinary dysfunction	Yes	89 (31.9)	21 (30.9)	0.886
	Not	190 (68.1)	47 (69.1)	
orthostatic hypotension	Yes	51 (16.2)	24 (27.9)	0.019
	Not	263 (83.8)	62 (72.1)	
depression	Yes	61 (26.6)	29 (43.9)	0.010
	Not	168 (73.4)	37 (56.1)	
hallucinations	Yes	7 (2.9)	6 (9.5)	0.031
	Not	236 (97.1)	57 (90.5)	
injuries	Patient	124 (53.2)	44 (71.0)	0.034
	Partner	33 (14.2)	7 (11.3)	
	Both	76 (32.6)	11 (17.7)	

Note: The phenoconverted subgroup (n = 121) is included within the overall cohort in this table. Subgroup-specific values are presented in Tables 1b and 2b.

males (53.2%; $p=0.034$). Injuries affecting the partner (11.3% females vs. 14.2% males) or both the patient and the partner (17.7% females vs. 33.6% males) were less common in females compared to males. To clarify the overall patient involvement, when injury categories were collapsed into “patient-involved” (self-directed or both) versus “partner-only,” the proportion of patient-involved injuries was 88.7% in women (55/62) and 85.8% in men (200/233), with no significant sex difference (Fisher’s exact $p=0.68$).

All 536 participants completed at least one follow-up visit; 217 were excluded from the Cox regression due to missing values in key variables ($n=216$) or automatic software exclusion before the first observed event in their stratum ($n=1$). The sex distribution did not differ significantly between included and excluded participants ($\chi^2=0.86$, $p=0.353$), indicating no evidence of sex-related exclusion bias. Overall, the median follow-up duration for the 319 participants included in the Cox regression analysis was 2.57 years. Follow-up intervals from iRBD diagnosis to the second clinical visit were also comparable between sexes: among converters, the median follow-up was 3.00 years in males and 2.73 years in females ($p=0.897$), and among censored participants, 2.53 years in males and 1.89 years in females ($p=0.271$). No differences in the risk of conversion between males and females were found (median time: females = 2.54 years; males = 2.64 years; $\beta=1.14$, 95% CI 0.72–1.81, $p=0.571$) (Figure 1).

No differences in the risk of conversion between males and females were found (median time: females = 2.54 years; males = 2.64 years; $\beta=1.14$, 95% CI 0.72–1.81, $p=0.571$)

(Figure 1). After stratification for injuries (patient and partner), orthostatic hypotension, depression, and history of hallucinations, a significantly higher risk of conversion was observed in women with a history of injuries affecting patients at first iRBD diagnosis ($\beta=2.61$, 95% CI 1.19–5.73, $p=0.017$) (Figure 2).

Discussion

In the present study, we observed a significant male predominance, with 4 out of 5 included patients being male, a finding consistent with previous research.² This disparity may be partially explained by the tendency for male patients to exhibit more aggressive and violent behaviors, potentially prompting them to seek medical attention more readily.¹² However, in women, injuries affecting patients at the first visit were significantly more frequent than injuries affecting the partner or both. Among men, the distribution was 53.2% for patient injuries, 14.2% for partner injuries, and 33.6% for injuries affecting both. This discrepancy may partly explain why women experience a longer latency between symptom onset and RBD diagnosis compared to men.

Biological factors such as the protective role of estrogen or a potential negative influence of androgens may also contribute to these differences.¹³ However, previous studies have found no abnormalities in sex-linked serum hormones in male iRBD patients.^{14,15} Furthermore, our data revealed that while the age at iRBD diagnosis was significantly higher in the female group, no statistical difference was observed regarding the age of disease onset. This aligns

Table 2b. Clinical data (categorical variables) for the phenoconversion group by sex at first medical examination and second medical examination (time of diagnosis of phenoconversion).

		First medical examination			Second medical examination		
		Males N (%)	Females N (%)	P value	Males N (%)	Females N (%)	P value
lesions	Yes	45 (61.6)	16 (80.0)	0.184	16 (28.1)	4 (22.2)	0.620
	Not	28 (38.4)	4 (20.0)		41 (71.9)	14 (77.8)	
oneiric status	Yes	48 (76.1)	14 (77.8)	0.581	22 (53.2)	2 (20.0)	0.166
	Not	15 (23.8)	4 (22.2)		25 (46.8)	8 (80.0)	
hyposmia	Yes	27 (50.0)	7 (41.2)	0.586	11 (26.8)	9 (60.0)	0.513
	Not	27 (50.0)	10 (58.8)		30 (73.2)	6 (40.0)	
constipation	Yes	32 (57.1)	9 (60.0)	0.226	40 (80.0)	10 (66.7)	0.488
	Not	24 (42.9)	6 (40.0)		10 (20.0)	5 (33.3)	
urinary dysfunction	Yes	19 (45.1)	2 (25.0)	0.441	29 (76.3)	6 (66.7)	0.674
	Not	23 (54.8)	6 (75.0)		9 (23.7)	3 (33.3)	
orthostatic hypotension	Yes	10 (19.2)	7 (43.7)	0.095	-	-	-
	Not	42 (80.8)	9 (56.3)				
depression	Yes	19 (57.6)	2 (20.0)	0.069	9 (45.5)	3 (50.0)	1.000
	Not	14 (42.4)	8 (80.0)		11 (55.5)	3 (50.0)	
hallucinations	Yes	2 (5.3)	3 (50.0)	0.013	20 (43.5)	3 (25.0)	0.329
	Not	36 (94.7)	3 (50.0)		26 (56.5)	9 (75.0)	
injuries	Patient	22 (48.9)	12 (75.0)	0.253	10 (66.7)	3 (100.0)	0.337
	Partner	8 (17.8)	1 (6.2)		1 (6.7)	0 (0.0)	
	Both	15 (33.3)	3 (18.8)		4 (26.6)	0 (0.0)	

Note: Differences in the number of participants between the first and second medical examinations reflect missing data for specific clinical variables at follow-up, due to incomplete documentation during clinical assessments. All participants attended both evaluations.

with other studies and may reflect not only greater symptom intensity and severity in male patients but also socio-ecological factors influencing the detection of abnormal nighttime behaviors by bed partners.^{16,17}

Gender disparity in education and cognitive performance

We identified a significant gender disparity in education, with males having higher educational attainment at the time of iRBD diagnosis. This finding reflects broader societal norms and historical educational policies, as cohorts born between 1920 and 1959 generally exhibited lower educational levels among women, a gap that has gradually narrowed.¹⁸ Education level differences have been identified as a key factor contributing to the gender gap in late-life cognition, particularly in developing countries.¹⁸

However, in our study, no significant gender differences were observed in cognitive test scores. Instead, we found a significant difference in the age at which these tests were administered, consistent with the older age at iRBD diagnosis in female patients.^{16,17}

Educational attainment may influence recognition and help-seeking for nocturnal behaviors (via health literacy, symptom awareness, and facility in accessing specialist services) and could therefore contribute to sex-related differences in presentation and referral. This possibility should be considered when interpreting our findings.

Clinical symptoms and injuries

Orthostatic hypotension, depressive symptoms, and hallucinations were more frequently observed in females than in males at the time of iRBD diagnosis. The higher prevalence of both cortical and subcortical symptoms observed in female participants may suggest a broader distribution of alpha-synucleinopathy compared with males in our cohort. This could be related, at least in part, to their older age at the time of diagnosis, which might allow more time for pathological spread. Additionally, in the phenoconverted subgroup, hallucinations and depressive symptoms were more frequently reported in female patients at their first visit. However, the number of phenoconverted female patients with available data on hallucinations was relatively small, which may introduce a reporting bias. This limitation should be considered when interpreting this finding, and larger samples may help to confirm and better quantify this association.

Notably, PD is more prevalent in males than females and exhibits distinct sex-related pathophysiological and clinical differences.¹⁹ Women with PD tend to experience more frequent and severe non-motor symptoms, including depression, autonomic dysfunction, pain, and hyposmia.^{19–22} Additionally, sex-related differences have been hypothesized to influence PD pathophysiology, particularly in mechanisms involving dopaminergic pathways, neuroinflammation, and oxidative stress.¹⁹

In DLB, a recent longitudinal study revealed sex-specific differences in the timing and presentation of symptoms.




Figure 1. Hazard function of the cox regression analysis of risk of conversion in males and females (model corrected by age at iRBD diagnosis). The observation period (time in months) was defined as the time between iRBD diagnosis and the next medical examination). $\beta = 1.14$, 95% CI 0.72–1.81, $p = 0.571$.

Men were found to experience probable RBD earlier than women and prior to the onset of cognitive symptoms.²³ Conversely, women with DLB were observed to present RBD concurrently with cognitive dysfunction and were more likely to experience visual hallucinations, which occurred earlier and more frequently in the disease course compared to male patients with DLB.²³ Furthermore, in the general population, women exhibit a higher prevalence of depressive symptoms compared to men.^{24–26} This disparity may result from a complex interplay of social, behavioral, educational, and biological factors.^{24–26}

At the time of iRBD diagnosis, women were more likely to report self-directed injuries, while men more frequently caused injuries to their bed partners. The longer diagnostic delay observed in females may be influenced both by the more frequent presence of self-directed injuries, which may be less apparent to others and thus less likely to prompt external concern, and by socio-ecological factors, such as living alone or being widowed, which may reduce the likelihood of early recognition by a partner. This pattern may partly reflect demographic differences, as

women in our cohort were less likely to have a bed partner and more frequently divorced or widowed, which could influence the proportion of self-directed versus partner injuries reported. Examples of socio-ecological factors include sleeping separately from a partner; partner-related limitations to observation (e.g., poor health, sensory impairment, or deep sleep); lower awareness of RBD symptoms; and reduced access or delayed referral to accredited sleep centers, all of which may delay recognition and reporting of nocturnal behaviors. Interestingly, this is consistent with findings from a recent large cohort study involving vPSG-confirmed RBD patients without parkinsonism, dementia, or narcolepsy, which reported that men were more likely to injure their bed partners than women (45% vs. 17%).²⁷ Regarding dream-enactment behaviors and related injuries, findings in the literature remain inconsistent. Early reviews and cohort studies did not identify sex-related differences in dream-related behaviors in iRBD patients.^{6,28,29} A recent meta-analysis also found no significant differences in the risk of sleep-related injuries. However, a systematic review suggested that women with




Figure 2. Hazard function of the Cox regression analysis of risk of conversion in men and women in the subgroup with history of injuries affecting patients at first iRBD diagnosis (model corrected by age at the iRBD diagnosis). The observation period (time) was defined as the time between iRBD diagnosis and the next medical examination). $\beta = 2.61$ (CI 1.19–5.73 p value 0.017).

RBD exhibit less dream-enacting and disruptive behaviors compared to men, which may contribute to a lower likelihood of seeking medical consultation.^{6,28}

In our cohort, these injury data were systematically collected through a standardized semi-structured interview, ensuring comparability across participants. This methodology allows a more reliable estimation of the prevalence of self-directed versus partner injuries at baseline and supports our finding of a higher frequency of self-directed injuries in women. Such differences may reflect sex-specific patterns of dream-enactment behaviors, differences in reporting, or sociocultural factors influencing symptom recognition and medical referral.

Given that participants were recruited from accredited Sleep Medicine Centers, our sample reflects a clinical sample rather than the general population. This recruitment context may introduce selection bias, including potential sex-related differences in referral patterns, symptom recognition, or healthcare-seeking behavior. These factors should be considered when interpreting the generalizability of our findings.

These discrepancies may stem from methodological differences, reporting biases, or variations in the rate of men and women with bed partners across studies. Regardless, a standardized approach to investigate this topic is essential, as RBD-associated behaviors can result in severe injuries to bed partners. Raising awareness about these risks and promoting education on preventive measures is critical.^{29–31}

Conversion risk and long-term follow-up

Consistent with our Results, the overall time-to-phenocconversion did not differ between sexes ($\beta = 1.14$, 95% CI 0.72–1.81; $p = 0.571$). In our cohort, a history of injuries affecting patients at first iRBD diagnosis was associated with a significantly higher risk of conversion in women. This injury-stratified observation is exploratory and hypothesis-generating and will require confirmation in larger samples with longer follow-up. To our knowledge, this finding has not been previously reported. One possible

explanation is that the diagnosis in women occurs at a later stage of neurodegeneration, when injuries are more prevalent, whereas in men, violent behaviours may manifest earlier. This is supported by evidence that men with iRBD exhibit more violent dream-enacting behaviours (e.g., punching or striking) and higher phasic muscle activity during REM sleep, suggesting earlier and more intense symptom onset.⁶ In our cohort, the overall phenoconversion rate was consistent with figures reported in previous longitudinal studies.³² As a detailed analysis of phenoconversion predictors in the FARPRESTO cohort is currently ongoing and not a primary aim of the present work, we provide here only a brief contextualization of these rates within the existing literature. A longer follow-up of our cohort is necessary to confirm this hypothesis.

Strengths and limitations

This study has several strengths and limitations. One limitation is the relatively small number of phenoconverted patients. In particular, the number of phenoconverted female participants was limited, which may reduce statistical power and increase variability, potentially underestimating sex-related differences. Other limitations include incomplete assessments for all subjects, the absence of objective biomarkers for disease progression, the lack of an injury assessment scale, and the absence of an evaluation of RBD symptom severity. However, these limitations may be addressed over time through ongoing recruitment and the prospective nature of the study.

The FARPRESTO study's standardized methodology and large, vPSG-confirmed iRBD cohort provide a valuable retrospective and prospective study opportunity. The inclusion of vPSG recordings, neuroimaging assessments, and socio-demographic criteria reduces biases such as diagnostic uncertainty and the presence of hypnological comorbidities or RBD mimics.

Conclusions

The present study highlights a male predominance in the iRBD sample, with female patients being older at iRBD diagnosis and more often reporting injuries affecting only themselves, while men more often reported injuries affecting both themselves and their bed partner; overall, the proportion of injuries involving the patient (self-directed or both) was similar between sexes. Females also showed higher rates of orthostatic hypotension, depressive symptoms, and hallucinations at iRBD diagnosis. These findings suggest that sex-related factors may influence the clinical expression of iRBD. Despite being older at iRBD diagnosis, women did not differ from men in time-to-phenoconversion in the overall analysis. In an exploratory stratified analysis, women with a history of injuries affecting the patient at diagnosis showed a higher conversion risk; this finding requires confirmation. This finding suggests a potential

protective factor against alpha-synucleinopathies associated with RBD in women. Furthermore, despite having less formal education, being of older age at the time of cognitive evaluation, and exhibiting a higher prevalence of hallucinations, factors that are generally recognized as risk elements for the development of dementia, women were as likely as men to develop DLB.

Future research is essential to elucidate the underlying mechanisms and support the development of tailored diagnostic and therapeutic approaches as new treatments become available.

Ethical considerations

This study adhered to the principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the local ethics committees of all participating FARPRESTO centers, and informed consent was obtained from all participants. The FARPRESTO study is registered at clinicaltrials.gov (NCT05262543).

Consent to participate

Informed consent to participate was written, for further information see clinicaltrials.gov (NCT05262543).

Author contributions

Michelangelo Maestri, Michela Figorilli, Francesca Ingravallo and Monica Puligheddu equally contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript.

Federico Meloni processed the experimental data, performed the analysis, and designed the figures.

Elisa Casaglia, Marcello Mario Mascia, Martina Mulas aided in interpreting the results and worked on the manuscript.

All authors discussed the results and commented on the manuscript.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Italian Ministry of health :PRIN: PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE – Bando 2022 Prot. 2022LSSAK7. This work is financed by Italian Association of Sleep Medicine who is the promoter of the FARPRESTO registry.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

1. Arnaldi D, Mattioli P, Pardini M, et al. Clinical and dopaminergic imaging characteristics of the FARPRESTO cohort of trial-ready idiopathic rapid eye movement sleep behavior patients. *Eur J Neurol* 2023 Dec; 30: 3703–3710.
2. Schenck CH, Bundlie SR, Ettinger MG, et al. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. *Sleep* 1986; 9: 293–308.

3. Li X, Zong Q, Liu L, et al. Sex differences in rapid eye movement sleep behavior disorder: a systematic review and meta-analysis. *Sleep Med Rev* 2023 Oct; 71: 101810.
4. International Classification of Sleep Disorders. [s.l.]: American Academy of Sleep Medicine; 2014.
5. Takeuchi N, Sasai-Sakuma T and Inoue Y. Gender differences in clinical findings and α -synucleinopathy-related markers in patients with idiopathic REM sleep behavior disorder. *Sleep Med* 2020 Feb; 66: 216–219.
6. Fernández-Arcos A, Iranzo A, Serradell M, et al. The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation: a study in 203 consecutive patients. *Sleep* 2016 Jan 1; 39: 121–132.
7. Raheel K, Deegan G, Di Giulio I, et al. Sex differences in alpha-synucleinopathies: a systematic review. *Front Neurol* 2023; 14: 1204104.
8. Puligheddu M, Figorilli M, Antelmi E, et al. Predictive risk factors of phenoconversion in idiopathic REM sleep behavior disorder: the Italian study “FARPRESTO”. *Neurol Sci* 2022 Dec; 43: 6919–6928.
9. International Classification of Sleep Disorders Third Edition. Text Revision Summary of Diagnostic Criteria Changes SUMMARY OF DIAGNOSTIC CRITERIA CHANGES.
10. Aiello EN, Pasotti F, Appollonio I, et al. Equating Mini-mental state examination (MMSE) and Montreal cognitive assessment (MoCA) scores: conversion norms from a healthy Italian population sample. *Aging Clin Exp Res* 2022 Jul; 34: 1721–1724.
11. Goetz CG, Stebbins GT and Tilley BC. Calibration of unified Parkinson’s disease rating scale scores to movement disorder society-unified Parkinson’s disease rating scale scores. *Mov Disord [Internet]* 2012 Sep 1; 27: 1239–1242. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22886777>.
12. Bodkin CL and Schenck CH. Rapid eye movement sleep behavior disorder in women: relevance to general and specialty medical practice. *J Womens Health (Larchmt)* 2009 Dec; 18: 1955–1963.
13. Liu B and Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson’s disease. *Clin Exp Pharmacol Physiol* 2007 Jul 18; 34: 555–565.
14. Chou KL, Moro-De-Casillas ML, Amick MM, et al. Testosterone not associated with violent dreams or REM sleep behavior disorder in men with Parkinson’s. *Mov Disord* 2007 Feb 15; 22: 411–414.
15. Iranzo A, Santamaría J, Vilaseca I, et al. Absence of alterations in serum sex hormone levels in idiopathic REM sleep behavior disorder. *Sleep* 2007 Jun; 30: 803–806.
16. Högl B, Arnulf I, Bergmann M, et al. Rapid eye movement sleep behaviour disorder: past, present, and future. *J Sleep Res* 2022 Aug; 31: e13612.
17. Takeuchi N, Sasai-Sakuma T and Inoue Y. Gender differences in clinical findings and α -synucleinopathy-related markers in patients with idiopathic REM sleep behavior disorder. *Sleep Med* 2020 Feb; 66: 216–219.
18. Angrisani M, Lee J and Meijer E. The gender gap in education and late-life cognition: evidence from multiple countries and birth cohorts. *J Econ Ageing* 2020 Jun; 16: 100232.
19. Cerri S, Mus L and Blandini F. Parkinson’s disease in women and men: what’s the difference? *J Parkinsons Dis* 2019; 9: 501–515.
20. Wissel BD, Dwivedi AK, Chin MA, et al. Functional neurological disorders in Parkinson disease. *J Neurol Neurosurg Psychiatry* 2018 Jun; 89: 566–571.
21. Martinez-Martin P, Falup Pecurariu C, Odin P, et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. *J Neurol* 2012 Aug; 259: 1639–1647.
22. Crispino P, Gino M, Barbagelata E, et al. Gender Differences and Quality of Life in Parkinson’s Disease. *Int J Environ Res Public Health* 2020 Dec 29; 18.
23. Choudhury P, Graff-Radford J, Aakre JA, et al. The temporal onset of the core features in dementia with Lewy bodies. *Alzheimers Dement* 2022 Apr; 18: 591–601.
24. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. *BMC Med* 2011 Jul 26; 9: 90.
25. Di Benedetto MG, Landi P, Mencacci C, et al. Depression in women: potential biological and sociocultural factors driving the sex effect. *Neuropsychobiology* 2024; 83: 2–16.
26. Van de Velde S, Bracke P and Levecque K. Gender differences in depression in 23 European countries. Cross-national variation in the gender gap in depression. *Soc Sci Med* 2010 Jul; 71: 305–313.
27. Elliott JE, Lim MM, Keil AT, et al. Baseline characteristics of the north American prodromal synucleinopathy cohort. *Ann Clin Transl Neurol* 2023 Apr 8; 10: 520–535.
28. McCarter SJ, St. Louis EK, Boswell CL, et al. Factors associated with injury in REM sleep behavior disorder. *Sleep Med* 2014 Nov; 15: 1332–1338.
29. Bodkin CL and Schenck CH. Rapid eye movement sleep behavior disorder in women: relevance to general and specialty medical practice. *J Womens Health* 2009 Dec; 18: 1955–1963.
30. Ingravallo F, Schenck CH and Plazzi G. Injurious REM sleep behaviour disorder in narcolepsy with cataplexy contributing to criminal proceedings and divorce. *Sleep Med* 2010 Oct; 11: 950–952.
31. Cramer Bornemann MA, Schenck CH and Mahowald MW. A review of sleep-related violence. *Chest* 2019 May; 155: 1059–1066.
32. Galbiati A, Verga L, Giora E, et al. The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies. In: *Vol. 43, Sleep medicine reviews*. W.B. Saunders Ltd, 2019, pp.37–46.